AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06450392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline - intravenous
Description: 0.9% IV Normal Saline
Study NCT04795934 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION
Description: LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION VERSUS LAPAROSCOPIC NISSEN FUNDOPLICATION
Study NCT06510270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 mg once daily
Description: Dapagliflozin 10 mg once daily will be given to all patients in symptomstic heart failure group
Study NCT06510270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loop diuretics
Description: Loop diuretics (IV or orally) will be given to all patients in symptomatic heart failure group
Study NCT06510270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatments of associated co-morbidities (e.g Anti-hypertensive, oral hypoglycemic)
Description: Treatment of associated co-morbidities will be given to both arms (group) such as anti-hypertensive (B blockers, ACIE, ARBS, CA channel blockers, Diuretics), oral hypoglycemic (Metformins, sulfonyl urea,.......)
Study NCT06510270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatments of associated co-morbidities (e.g Anti-hypertensive, oral hypoglycemic)
Description: Treatment of associated co-morbidities will be given to both arms (group) such as anti-hypertensive (B blockers, ACIE, ARBS, CA channel blockers, Diuretics), oral hypoglycemic (Metformins, sulfonyl urea,.......)
Study NCT05069220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MFBG
Description: Patients with neuroendocrine malignancies receive 2-4 MBq/kg of 18F-MFBG intravenously followed by PET/CT after 60min of injection.
Study NCT05069220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Dotatate
Description: Patients with malignant PPGL and NB receive intravenously 68Ga-Dotatate followed by PET/CT after 40min of injection.
Study NCT06480539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The comparator is a placebo, namely pure saline (NaCl 0.9%), which will be administered following the same regimen as the intervention.
Study NCT06480539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Nocturnal administration of dexmedetomidine (0.2-1.0 mcg/kg/h) during the first night after surgery. Dexmedetomidine infusion, not preceded by a bolus administration, will be started at 0.4 mcg/kg/h in the intervention group at 8 p.m. the day of surgery. Dexmedetomidine infusion will be titrated every 30 minutes with 0.1 mcg/kg/h steps until a RASS of -1 to -3 (drowsy, light to moderate sedation) is reached. The infusion will be discontinued at 6 a.m. the next morning.
Study NCT05711251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity in Health Promotion
Description: During the term, the participants in the study group took lessons on many subjects, from the benefits of physical activity to suggestions to increase physical activity at work and in daily life.
Study NCT06753539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ILM forceps - membrane grasping
Description: grasping the epiretinal membrane at the starting location, using pinch peeling, is performed with an ILM forceps.
Study NCT06753539 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ILM forceps - membrane grasping
Description: grasping the epiretinal membrane at the starting location, using pinch peeling, is performed with an ILM forceps.
Study NCT05106296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be taken by mouth once daily, on days 1-21 of each treatment cycle.
Study NCT05106296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be taken by mouth twice daily, throughout each treatment cycle.
Study NCT05106296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
Study NCT05106296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
Study NCT05563779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume Control mode
Description: Volume Control mode for mechanical ventilation
Study NCT05563779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Control mode
Description: Pressure Control mode for mechanical ventilation
Study NCT05563779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive Pressure Control mode
Description: Adaptive Pressure Control mode for mechanical ventilation
Study NCT06468800 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TRACMOTION
Description: Patients already scheduled for ESD will undergo an ESD procedure with the aid of the Tracmotion device
Study NCT06014190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20089
Description: All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.
Study NCT06409598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-immersive virtual reality home-based exercise.
Description: This intervention aims include some exercises in the form of games to facilitate and improve the upper limb functions and static balance from sitting and standing positions among chronic stroke survivors.
Study NCT05029791 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tumor biopsy
Description: 2 cutaneous tumor biopsies before treatment initiation (D-28 to D-1) and under treatment (Month 1)
Study NCT05029791 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: 1 EDTA blood sample (8mL) before treatment initiation (D-28 to D-1)
Study NCT05320315 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Foto Ultra ISDIN® Solar Allergy Fusion Fluid
Description: The tested MD is a very high protection sunscreen
Study NCT06751966 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination Product: Conventional third-line therapy
Description: Conventional third-line therapy includes oral chemotherapy drugs and/or targeted cancer drugs. The medication, dosage and treatment cycle of oral chemotherapy drugs and/or targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances.
Study NCT06751966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-based peptide vaccine
Description: The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study NCT06752057 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-loaded DC vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.
Study NCT06752057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
Study NCT06752057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-loaded DC vaccine
Description: The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study NCT06752746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011
Description: Multiple dose
Study NCT06752772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart watch
Description: Participants are required to wear the study issued smart watch for at least 8 hours a day during the intervention period and are encouraged to wear it beyond the study intervention period.
Study NCT06752772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart watch
Description: Participants are required to wear the study issued smart watch for at least 8 hours a day during the intervention period and are encouraged to wear it beyond the study intervention period.
Study NCT06752772 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dashboard with nudging system
Description: Nudges will be sent to participants' smart watch/mobile application with messages that are designed to motivate them to lead a healthy lifestyle.
Study NCT06752772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dashboard with nudging system
Description: Nudges will be sent to participants' smart watch/mobile application with messages that are designed to motivate them to lead a healthy lifestyle.
Study NCT06752772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Health Coach (DHC)
Description: Participants will be assigned to a DHC and the DHC will be providing them with remote health coaching assistance for a duration of 6 months, upon successful enrolment.
Study NCT06754956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The patient will receive two intravenous injections of the same gadoterate meglumine contrast agent.
Description: Each patient will undergo two different field strength HR-VWIs with enhancement, and on each occasion the patient will be injected with contrast DOTAREM (gadoterate meglumine) .
Study NCT06752915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acupressure application
Description: Acupressure massage will be applied to LI4, HT7, LU1 and ST 36 acupuncture points for 2 minutes.
Study NCT06752993 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory Muscle Strength Training (EMST-150)
Description: Training is going to perform by using a pressure treshold-loading device (EMST-150, Aspire Products, LLC, Gainesville, FL) used to exhale against a same-pressure load every exhalation for strengthening primarily the core muscles. The device pressure is adjusted according to PEmax and reliability/reproducibility has been demonstrated.
Study NCT06752993 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: Training is going to perform by using a pressure treshold-loading device (EMST-150, Aspire Products, LLC, Gainesville, FL) without physiological load. The sham device closely resembled the EMST device, with the only difference being that the pressure release valve was rendered nonfunctional by removing the spring. As a result, it exerted minimal to no physiological load on the targeted muscles.
Study NCT06755788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RT-CGM
Description: In the RT-CGM group, patients will wear a CGM sensor the day before surgery. Before entering the operating room, capillary blood glucose will be measured and compared with CGM interstitial glucose values for calibration. The target range for intraoperative blood glucose management is 3.9-10.0 mmol/L, with arterial blood gas measurements required at least every 2 hours. Following the administration of insulin or glucose, arterial blood gases should be retested at least every hour. RT-CGM monitoring will also be employed during surgery. A tablet in the operating room will be configured with low and high glucose alerts set at 3.9 mmol/L and 10.0 mmol/L, respectively. When an alarm is triggered, arterial blood gases will be rechecked, and glucose levels will be adjusted based on the arterial blood glucose results. If interstitial glucose values do not reach the intervention threshold, arterial blood gas measurements are recommended every 30 minutes.
Study NCT06755788 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Control
Description: In the control group, patients will wear a CGM sensor the day before surgery. Before entering the operating room, capillary blood glucose will be measured and compared with CGM interstitial glucose values for calibration. The target range for intraoperative blood glucose management is 3.9-10.0 mmol/L, with arterial blood gas measurements required at least every 2 hours. Following the administration of insulin or glucose, arterial blood gases should be retested at least every hour. CGM monitoring will also be employed during surgery, but the CGM interstitial glucose readings and alerts will be masked during the operation. The final intraoperative glucose management approach will be determined by the anesthesiologist, considering the patient's condition and surgical circumstances. The anesthesiologist can choose the intravenous insulin adjustment protocol we recommend.
Study NCT06755944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XY03-EA
Description: The sample size was 360 patients, and 72patients were treated with XY03-EA 150 mg, 300mgA group ,300mgBgroup,450mg and placebo respectively. The 150mg group took two tablets of placebo and one tablet of XY03-EA once, three times a day. For 90 days The 300mg A-group took one tablet of placebo and two tablets of XY03-EA once,three times a day. For 90 days The 300mg B-group took one tablet of placebo and two tablets of XY03-EA once,three times a day. Use continuously for 14 days.Placebo is used for 15-90 days.~The 450mg group took three tablets of XY03-EA once,three times a day. For 90 days.~The placebo group took three tablets of placebo once ,three times a day.For 90 days.
Study NCT06755944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XY03-EA
Description: The sample size was 360 patients, and 72patients were treated with XY03-EA 150 mg, 300mgA group ,300mgBgroup,450mg and placebo respectively. The 150mg group took two tablets of placebo and one tablet of XY03-EA once, three times a day. For 90 days The 300mg A-group took one tablet of placebo and two tablets of XY03-EA once,three times a day. For 90 days The 300mg B-group took one tablet of placebo and two tablets of XY03-EA once,three times a day. Use continuously for 14 days.Placebo is used for 15-90 days.~The 450mg group took three tablets of XY03-EA once,three times a day. For 90 days.~The placebo group took three tablets of placebo once ,three times a day.For 90 days.
Study NCT06752681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAY301
Description: DAY301 will be administered as IV infusion
Study NCT06754085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florastamin[18F] Injection
Description: The subjects will be intravenously injected with a single dose of 7±1 mCi (259±37 MBq) of Florastamin\[18F\] Injection and undergo PET/CT scan at 60-110 min after the injection.
Study NCT06752473 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KSD-101
Description: Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
Study NCT06752889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group( 1): Control Group (pulpectomy using zic oxide eugenol based sealer Zical):
Description: Zinc oxide eugenol based sealer (Zical) will be mixed into a thick paste and packed into the pulp chamber to fill the canal.
Study NCT06752889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group ( 2) Experimental group modified 3-MIX-TATIN):
Description: Modified 3Mix-tatin will be prepared by mixing three commercially available antibiotics with simvastatin. This powder will be mixed with zinc oxide eugenol based sealer called Zical which will act as a carrier or vehicle to form a creamy paste of 3Mixtatin at the time of application
Study NCT06752200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal splints fabricated using a fully digital workflow including the use of a jaw tracking device.
Description: Occlusal splints fabricated using a fully digital workflow including the use of a jaw tracking device.
Study NCT06752200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal splints fabricated using a combined digital workflow using a conventional bite technique
Description: upper and lower arches will be scanned intraorally. The bite will be registered at centric by using rubber base bite registration material after patient deprogramming with Lucia jig. Then the bite will be scanned. The splint will be designed and printed in the same workflow as the intervention group.
Study NCT06754072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Keyboard (VK) System
Description: Participants underwent a 4-week training program comprising 12 one-hour sessions to enhance finger individuation and motor control using a virtual reality platform.
Study NCT06755541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate in Combination With Ursodeoxycholic Acid
Description: Experimental: Fenofibrate 200 mg Capsules
Study NCT06755827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation and self-monitoring to treat pediatric obesity
Description: Participants will attend telehealth group sessions once weekly and be asked to self-monitor their mood and health behaviors daily between sessions.
Study NCT06755827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Participants who are randomized to the control group will receive an online, one-time, self-led psychoeducation program with information about current daily sleep, diet, and physical activity recommendations (e.g., information about sleep hygiene, the food pyramid, and recommendations for 60 minutes of moderate-to-vigorous physical activity daily).
Study NCT06753526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NSAID
Description: For 1st group of patients
Study NCT06753526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginine, 500 Mg Oral Capsule
Description: group 2by twice dose
Study NCT06753526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin 0.4 mg QD
Description: group 3 by once per day
Study NCT06753253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling Exercise
Description: Each arm will perform a 20-minute cycling intervention on an airdyne bike at different exercise intensity levels. Participants will perform the intervention three times over the course of one week.
Study NCT06752499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized online rTMS
Description: 5 Hz rTMS is applied to the MRI-localized hotspot on the affected hemisphere when the patients are performing motor tasks.
Study NCT06752499 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-individualized online rTMS
Description: 5 Hz rTMS is applied to the conventional hotspot on the affected hemisphere when the patients are performing motor tasks.
Study NCT06752499 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham rTMS is applied to the MRI-localized hotspot on the affected hemisphere when the patients are performing motor tasks.
Study NCT06754059 — intervention group
Intervention type: DRUG
Intervention: Pyrotinib
Description: In this study, after at least 4 cycles of taxoid chemotherapy combined with trastuzumab ± pertuzumab, the evaluation result reached SD, CR or PR, and capecitabine combined with pyrotinib + trastuzumab was given successively in the later period (capecitabine was used for 4-6 cycles
Study NCT06751771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comprehensive correcting exercise program
Description: Group A will be treated with comprehensive correcting exercise program (three times a week for 6 weeks) into 3 phases with different intensity and frequency
Study NCT06751771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie's method of exercises
Description: Group B will receive the McKenzie's method of exercises that include Deep neck flexor (chin tucks), Shoulders shrug McKenzie exercise for neck, Repeated shoulder flexion/Extension, Neck flexion McKenzie exercises
Study NCT02891967 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: bulk fill composite
Description: cavities will be incrementally layered with resin composite and each increment will be cured as directed by the manufacturer with the light curing unit (XL 3000; 3M/eSPe), with an energy higher than 450 mW/cm² (±50 mw/cm²)
Study NCT02891967 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nano resin composite (K Z350 xt)
Description: cavities will be restored by bulk fill composite (3M ESPE) as one increment then will be cured as directed by the manufacturer with the light curing unit.
Study NCT06753123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A workplace-based depression intervention for low-wage hospital workers
Description: This intervention is a remotely delivered workplace-based depression intervention that is tailored to the specific social and behavioral needs of low-wage hospital service workers. The intervention involves assessment of depression-related work impairment, work-focused cognitive behavioral therapy, work coaching, social needs screening and referral, and text message support for mood and physical activity.